THTX vs. IOVA, ARVN, SAGE, AMLX, TBPH, ATAI, KROS, TLRY, MNMD, and ORGO
Should you be buying Theratechnologies stock or one of its competitors? The main competitors of Theratechnologies include Iovance Biotherapeutics (IOVA), Arvinas (ARVN), Sage Therapeutics (SAGE), Amylyx Pharmaceuticals (AMLX), Theravance Biopharma (TBPH), atai Life Sciences (ATAI), Keros Therapeutics (KROS), Tilray Brands (TLRY), Mind Medicine (MindMed) (MNMD), and Organogenesis (ORGO). These companies are all part of the "pharmaceutical products" industry.
Theratechnologies vs. Its Competitors
Iovance Biotherapeutics (NASDAQ:IOVA) and Theratechnologies (NASDAQ:THTX) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, dividends, earnings, risk, analyst recommendations, valuation and profitability.
Theratechnologies has a net margin of -10.85% compared to Iovance Biotherapeutics' net margin of -176.49%. Theratechnologies' return on equity of 0.00% beat Iovance Biotherapeutics' return on equity.
77.0% of Iovance Biotherapeutics shares are owned by institutional investors. 10.3% of Iovance Biotherapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Iovance Biotherapeutics currently has a consensus price target of $12.22, suggesting a potential upside of 530.01%. Given Iovance Biotherapeutics' higher possible upside, equities research analysts plainly believe Iovance Biotherapeutics is more favorable than Theratechnologies.
In the previous week, Iovance Biotherapeutics had 39 more articles in the media than Theratechnologies. MarketBeat recorded 43 mentions for Iovance Biotherapeutics and 4 mentions for Theratechnologies. Iovance Biotherapeutics' average media sentiment score of 0.19 beat Theratechnologies' score of 0.05 indicating that Iovance Biotherapeutics is being referred to more favorably in the media.
Theratechnologies has lower revenue, but higher earnings than Iovance Biotherapeutics. Theratechnologies is trading at a lower price-to-earnings ratio than Iovance Biotherapeutics, indicating that it is currently the more affordable of the two stocks.
Iovance Biotherapeutics has a beta of 0.85, suggesting that its stock price is 15% less volatile than the S&P 500. Comparatively, Theratechnologies has a beta of 0.55, suggesting that its stock price is 45% less volatile than the S&P 500.
Summary
Iovance Biotherapeutics beats Theratechnologies on 10 of the 17 factors compared between the two stocks.
Get Theratechnologies News Delivered to You Automatically
Sign up to receive the latest news and ratings for THTX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding THTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Theratechnologies Competitors List
Related Companies and Tools
This page (NASDAQ:THTX) was last updated on 7/16/2025 by MarketBeat.com Staff
Free THTX Stock Alerts